INC Research ($INCR) appointed Judith Ng-Cashin to serve as its chief scientific officer, picking up a physician with stints at CRO giant Quintiles ($Q) and pharma magnate GlaxoSmithKline ($GSK) on her resume.
Ng-Cashin comes to INC after four years at Quintiles that saw her serve as vice president of medical strategy and vice president of advisory services. Before that, she spent 9 years at GSK in leadership roles that spanned risk management, infectious disease R&D and dermatology development.
At INC, she'll be responsible for integrating the CRO's therapeutic expertise with practical medical experience, the company said. That means handling "scientific, medical and ethical governance matters, including collaboration with key medical and scientific stakeholders," INC said in a statement.
Meanwhile, fast-growing INC is projecting record revenue of more than $1 billion in 2016, good for nearly 10% annual growth.
The North Carolina company raised $150 million in a 2014 IPO and has grown to employ about 6,400 people in more than 50 countries.
- read the statement